Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS8034932 B2
Publication typeGrant
Application numberUS 11/793,418
PCT numberPCT/GB2005/004999
Publication dateOct 11, 2011
Filing dateDec 22, 2005
Priority dateDec 24, 2004
Fee statusPaid
Also published asCA2589775A1, CN101084197A, CN101084197B, EP1871747A2, EP2361906A1, US20080207903, WO2006067456A2, WO2006067456A3
Publication number11793418, 793418, PCT/2005/4999, PCT/GB/2005/004999, PCT/GB/2005/04999, PCT/GB/5/004999, PCT/GB/5/04999, PCT/GB2005/004999, PCT/GB2005/04999, PCT/GB2005004999, PCT/GB200504999, PCT/GB5/004999, PCT/GB5/04999, PCT/GB5004999, PCT/GB504999, US 8034932 B2, US 8034932B2, US-B2-8034932, US8034932 B2, US8034932B2
InventorsMichael Butters, Steven Robert LENGER, Paul Michael Murray, Evan William Snape
Original AssigneeAstrazeneca Uk Limited
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Chemical process
US 8034932 B2
Abstract
A process for formation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, (A chemical formula should be inserted here—please see paper copy enclosed herewith) I via a Heck reaction is described. Intermediates useful in the process and processes for making said intermediates are also described.
Images(24)
Previous page
Next page
Claims(12)
1. A process for the manufacture of a compound of formula I
or a pharmaceutically acceptable salt thereof,
which comprises reacting a compound of formula II,
wherein
L is a leaving group and
X is a group Z which is N-(methyl)methylsulfonylamino (CH3SO2N(CH3)—);
with a compound of the formula III,
wherein
A is selected from a group (i) to (vii) below,
wherein P1 and P2 are independently selected from hydrogen and a hydroxy protecting group, or
P1 together with P2 form a 1,3-dihydroxy protecting group;
P3 is hydrogen or a hydroxy protecting group;
P4 and P5 are independently selected from hydrogen and a hydroxy protecting group, or P4 together with P5 form a 1,3-dihydroxy protecting group, and
P6 and P7 are independently a hydroxy protecting group; or P5 together with P6 form a 1,3-dihydroxy protecting group, and P4 is hydrogen or a hydroxy protecting group and P7 is a hydroxy protecting group;
P8 is hydrogen or a hydroxy protecting group;
P9 is hydrogen or a hydroxy protecting group;
P10 and P11 are independently selected from hydrogen and a hydroxy protecting group, or P10 together with P11, or P11 together with R4, form a 1,3-dihydroxy protecting group;
and unless otherwise stated R1, R2, R3 and R4 are independently carboxy protecting groups;
in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base;
followed by
(a) when A is a group (i), carrying out in any order the steps of (1) when P1 is a hydroxy protecting group, removal of the protecting group P1; (2) when P2 is a hydroxy protecting group, removal of the protecting group P2; and (3) removal of the protecting group R1;
(b) when A is a group (ii), carrying out in any order the steps of (1) asymmetric reduction of the carbonyl group adjacent to the carbon-carbon double bond; (2) when P3 is a hydroxy protecting group, removal of the protecting group P3; and (3) removal of the protecting group R2;
(c) when A is a group (iii), carrying out in any order the steps of (1) when P4 is a hydroxy protecting group, removal of the protecting group P4; (2) when P5 is a hydroxy protecting group, removal of the protecting group P5; (3) removal of the protecting group P6; and (4) removal of the protecting group P7;
(d) when A is a group (iv), carrying out in any order the steps of (1) when P8 is a hydroxy protecting group, removal of the protecting group P8; (2) asymmetric hydration of the carbon-carbon double bond adjacent to the ester group COOR3; and (3) removal of the protecting group R3;
(e) when A is a group (v), carrying out in any order the steps of (1) when P9 is a hydroxy protecting group, removal of the protecting group P9; and (2) hydrolysis under basic conditions;
(f) when A is a group (vi), carrying out in any order the steps of (1) asymmetric hydration of the ring carbon-carbon double bond; and (2) hydrolysis under basic conditions; and
(g) when A is a group (vii), carrying out in any order the steps of (1) asymmetric reduction of the carbon-carbon double bond adjacent to the group COOR4; (2) when P10 is a hydroxy protecting group, removal of the protecting group P10; (3) when P11 is a hydroxy protecting group, removal of the protecting group P11; and (4) removal of the protecting group R4; whereafter, when the product is obtained in the free acid form, optionally forming a pharmaceutically acceptable salt of the compound of formula I, or when the product is obtained as a salt, optionally converting the product to a different pharmaceutically acceptable salt.
2. The process as claimed in claim 1 wherein A is the group (i) as defined in claim 1.
3. A process for the manufacture of a compound of the formula IV
wherein P1 and P2 are independently hydroxy-protecting groups, or P1 together with P2 form a 1,3-dihydroxy protecting group, X is the group Z as defined in claim 1, and R1 is a carboxy protecting group, which comprises reacting a compound of the formula II as defined in claim 1 wherein X is the group Z as defined in claim 1 and L is a leaving group, with a compound of the formula III as defined in claim 1 wherein A is a group (i) as defined in claim 1 and P1 and P2 are independently hydroxy-protecting groups, or P1 together with P2 form a 1,3-dihydroxy protecting group, and R1 is a carboxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base.
4. A process for the manufacture of a compound of the formula V
wherein P3 is hydrogen or a hydroxy-protecting group, X is the group Z as defined in claim 1, and R2 is a carboxy protecting group comprising reacting a compound of the formula II as defined in claim 1 wherein X is the group Z as defined in claim 1 and L is a leaving group with a compound of the formula III as defined in claim 1 in which A is a group (ii) as defined in claim 1 wherein P3 is a hydrogen or a hydroxy-protecting group and R2 is a carboxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base.
5. A process for the manufacture of a compound of the formula VI
wherein P4, P5, P6 and P7 are independently hydroxy-protecting groups, or P4 together with P5 or P5 together with P6 form a 1,3-dihydroxy protecting group, and X is the group Z as defined in claim 1, comprising reacting a compound of the formula II as defined in claim 1 wherein X is the group Z as defined in claim 1 and L is a leaving group, with a compound of the formula III as defined in claim 1 in which A is a group (iii) as defined in claim 1 wherein P4, P5, P6 and P7 are independently hydroxy-protecting groups, or P4 together with P5 or P5 together with P6 form a 1,3-dihydroxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base.
6. A process for the manufacture of a compound of the formula VII
wherein P8 is a hydroxy-protecting group, X is the group Z as defined in claim 1, and R3 is a carboxy protecting group comprising reacting a compound of the formula II as defined in claim 1 wherein X is the group Z as defined in claim 1 and L is a leaving group with a compound of the formula III as defined in claim 1 in which A is a group (iv) as defined in claim 1 wherein P8 is a hydroxy-protecting group and R3 is a carboxy protecting group, in the presence of a catalytically effective amount of palladium catalyst and in the presence of a base.
7. A process for the manufacture of a compound of the formula VIII
wherein P9 is hydrogen or a hydroxy-protecting group and X is the group Z as defined in claim 1, comprising reacting a compound of the formula II as defined in claim 1 wherein X is the group Z as defined in claim 1 and L is a leaving group with a compound of the formula III as defined in claim 1 in which A is a group (v) as defined in claim 1 wherein P9 is a hydroxy-protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base.
8. A process for the manufacture of a compound of the formula IX
wherein X is the group Z as defined in claim 1, comprising reacting a compound of the formula II as defined in claim 1 wherein X is the group Z as defined in claim 1 and L is a leaving group with a compound of the formula III as defined in claim 1 in which A is a group (vi) as defined in claim 1, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base.
9. A process for the manufacture of a compound of the formula X
wherein P10 and P11 are independently selected from hydrogen and a hydroxy protecting group, or P10 together with P11, or P11 together with R4, form a 1,3-dihydroxy protecting group; X is the group Z as defined in claim 1; and R4 is a carboxy protecting group comprising reacting a compound of the formula II as defined in claim 1 wherein X is the group Z as defined in claim 1 and L is a leaving group, with a compound of the formula III as defined in claim 1 in which A is a group (vii) as defined in claim 1 wherein P10 and P11 are independently selected from hydrogen and a hydroxy protecting group, or P11 together with P11 form a 1,3-dihydroxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base.
10. The process as claimed in any of claim 1 or 3-9 wherein the palladium catalyst is bis(tri-tert-butylphosphine)palladium (0).
11. The process as claimed in any of claim 1 or 3-9 wherein the base is ammonia or a bulky tertiary amine.
12. The process as claimed in any of claim 1 or 3-9 wherein the reaction is carried out in a solvent selected from water, water and N,N-dimethylformamide and water and N,N-dimethylacetamide.
Description

This invention concerns a novel chemical process, and more particularly it concerns a novel chemical process for the manufacture of rosuvastatin and its pharmaceutically acceptable salts, especially rosuvastatin calcium, as well novel intermediates used in said process and processes for the manufacture of the novel intermediates.

Rosuvastatin and its pharmaceutically acceptable salts are HMG CoA reductase inhibitors and have use in the treatment of, inter alia, hypercholesterolemia and mixed dyslipidemia. Rosuvastatin calcium is marketed under the trademark CRESTOR™. European Patent Application, Publication No. (EPA) 0521471 discloses (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid (rosuvastatin) and its sodium salt and calcium salt (rosuvastatin calcium, illustrated below) and a process for their preparation.

Rosuvastatin and its pharmaceutically acceptable salts are obtained therein by condensation of methyl (3R)-3-[(tert-butyldimethylsilyl)oxy]-5-oxo-6-triphenylphosphoranylidene hexanoate with 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)-5-pyrimidinecarboxaldhyde, followed by deprotection of the 3-hydroxy group, asymmetric reduction of the 5-oxo group and hydrolysis.

Other processes for the preparation of rosuvastatin and its pharmaceutically acceptable salts are described in WO 00/49014 and WO 04/52867. The compound and its pharmaceutically acceptable salts are obtained in WO 00/49104 by reaction of diphenyl[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylmethyl]phosphine oxide with tert-butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl}acetate in the presence of a base, followed by removal of protecting groups. WO 04/52867 discloses the condensation of 1-cyano-(2S)-2-[(tert-butyldimethylsilyl)oxy-4-oxo-5-triphenylphosphoranylidene pentane with 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)-5-pyrimidinecarboxaldhyde, followed by deprotection, asymmetric reduction of the 4-oxo group and hydrolysis.

However there is a continuing need to identify alternative processes for the manufacture of rosuvastatin and its pharmaceutically acceptable salts. Such processes may, for example, when compared to previously known processes, be more convenient to use, be more suitable for large scale manufacture, give the product in a better yield, reduce the number of steps involved, use intermediates which are more easily isolated, require less complex purification techniques, use less expensive reagents and/or be more environmentally friendly.

WO 03/004450 (Ciba Specialty Chemicals) discloses a process for preparation of heptanoic acid derivatives and their use as intermediates in the synthesis of statin derivatives. WO 03/018555 (Ciba Specialty Chemicals) discloses a process for preparation of indole derivatives, such as fluvastatin. EP252476 (Warner Lambert) discloses compounds which are HMG CoA reductase inhibitors and a process for their synthesis.

We have now discovered a particularly useful process for preparing rosuvastatin and its pharmaceutically acceptable salts.

According to a first aspect of the invention, there is provided a process for the manufacture of a compound of formula I


or a pharmaceutically acceptable salt thereof,
which comprises reaction of a compound of formula II,


wherein L is a leaving group and X is a group Z which is N-(methyl)methylsulfonylamino (CH3SO2N(CH3)—) or X is a group Y which is a group that is capable of conversion into the group Z,
with a compound of the formula III,


wherein
A is selected from a group (i) to (vii) below,


wherein P1 and P2 are independently selected from hydrogen and a hydroxy protecting group, or P1 together with P2 form a 1,3-dihydroxy protecting group;
P3 is hydrogen or a hydroxy protecting group;
P4 and P5 are independently selected from hydrogen and a hydroxy protecting group, or P4 together with P5 form a 1,3-dihydroxy protecting group, and P6 and P7 are independently a hydroxy protecting group; or P5 together with P6 form a 1,3-dihydroxy protecting group, and P4 is hydrogen or a hydroxy protecting group and P7 is a hydroxy protecting group;
P8 is hydrogen or a hydroxy protecting group;
P9 is hydrogen or a hydroxy protecting group;
P10 and P11 are independently selected from hydrogen and a hydroxy protecting group, or P10 together with P11, or P11 together with R4, form a 1,3-dihydroxy protecting group; and unless otherwise stated R1, R2, R3 and R4 are independently carboxy protecting groups;
in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base;
followed by
(a) when X is a group Y, the group Y is converted into the group Z; followed by
(b) when A is a group (i), carrying out in any order the steps of (1) when P1 is a hydroxy protecting group, removal of the protecting group P1; (2) when P2 is a hydroxy protecting group, removal of the protecting group P2; and (3) removal of the protecting group R1;
(c) when A is a group (ii), carrying out in any order the steps of (1) asymmetric reduction of the carbonyl group adjacent to the carbon-carbon double bond; (2) when P3 is a hydroxy protecting group, removal of the protecting group P3; and (3) removal of the protecting group R2;
(d) when A is a group (iii), carrying out in any order the steps of (1) when P4 is a hydroxy protecting group, removal of the protecting group P4; (2) when P5 is a hydroxy protecting group, removal of the protecting group P5; (3) removal of the protecting group P6; and (4) removal of the protecting group P7;
(e) when A is a group (iv), carrying out in any order the steps of (1) when P8 is a hydroxy protecting group, removal of the protecting group P8; (2) asymmetric hydration of the carbon-carbon double bond adjacent to the ester group COOR3; and (3) removal of the protecting group R3;
(f) when A is a group (v), carrying out in any order the steps of (1) when P9 is a hydroxy protecting group, removal of the protecting group P9; and (2) hydrolysis under basic conditions;

(g) when A is a group (vi), carrying out in any order the steps of (1) asymmetric hydration of the ring carbon-carbon double bond; and (2) hydrolysis under basic conditions; and

(h) when A is a group (vii), carrying out in any order the steps of (1) asymmetric reduction of the carbon-carbon double bond adjacent to the group COOR4; (2) when P10 is a hydroxy protecting group, removal of the protecting group P10; (3) when P11 is a hydroxy protecting group, removal of the protecting group P11; and (4) removal of the protecting group R4;

whereafter, when the product is obtained in the free acid form, optionally forming a pharmaceutically acceptable salt of the compound of formula I, or when the product is obtained as a salt, optionally converting the product to a different pharmaceutically acceptable salt.

For the avoidance of doubt, the carbon atom bearing the group OP1 in the group A(i) is attached directly to the carbon-carbon double bond of formula III, and the groups A(ii) to A(vii) are attached in a likewise manner.

It will be appreciated that tautomeric forms of the groups A are also included within the scope of the present invention. For example, when A is a group (vii) in which P11 is hydrogen, this may exist in the keto form shown below.

Suitable palladium catalysts are, for example, those disclosed in J. Am. Chem. Soc., 2001, 123, 6989-7000 (which reference and more particularly the palladium catalysts described therein are hereby incorporated herein by reference), and analogous palladium catalysts, for carrying out the so-called Heck reaction. Although the Heck reaction is well known in the art for coupling certain aryl and heteroaryl halides (or triflates or acid chlorides) with alkenes, it has surprisingly been found that the Heck reaction can be carried out with a fully substituted, sterically-hindered 6-membered pyrimidine of formula II.

Particularly suitable palladium catalysts include, for example, those with trialkylphosphine ligands (Pd/P(alkyl)3), especially bis(tri-tert-butylphosphine)palladium (0). A Pd/P(alkyl)3 catalyst wherein the alkyl group is tert-butyl, such as a mixture of Pd2(dba)3 and P(t-Bu)3, may also be used.

The term “catalytically effective amount” means an amount from 1 mol % to 30 mol %, particularly from 2 mol % to 20 mol %, and more particularly from 5 mol % to 10 mol %, based on the amount of the compound of formula II.

The compounds of formula II and III are generally reacted together in the ratio of about 1 to 1.

Generally the reaction is carried out in a suitable solvent such as toluene, diphenyl ether and poly(ethylene glycol), and particularly N,N-dimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide, or dimethylsulfoxide, and more particularly water and binary mixtures of water and N,N-dimethylformamide and N,N-dimethylacetamide.

Generally the reaction is carried out at a temperature in the range 30-110° C., particularly 40-80° C., more particularly 50-60° C.

Suitable bases for use in the process of the invention include, for example, amine bases, such as ammonia, and particularly bulky tertiary amines such as N-methyldicyclohexylamine, used either stoichiometrically or catalytically with a stoichiometric amount of an inorganic base, such as cesium carbonate.

The reaction may also optionally be carried out in the presence of a tetrabutylammonium salt, such as tetrabutylammonium chloride or tetrabutylammonium tetrafluoroborate.

Particularly combinations of palladium catalyst, solvent and base (optionally in the presence of a tetrabutylammonium salt), which are suitable for carrying out the process of the invention, include the following:

Bis(tri-tert-butylphosphine)palladium (0), water, N,N-dicyclohexylmethylamine;

Bis(tri-tert-butylphosphine)palladium (0), water, N,N-dicyclohexylmethylamine, tetrabutylammonium chloride;

Bis(tri-tert-butylphosphine)palladium (0), water, N,N-dicyclohexylmethylamine, tetrabutylammonium tetrafluoroborate;

Bis(tri-tert-butylphosphine)palladium (0), toluene, N,N-dicyclohexylmethylamine, tetrabutylammonium chloride;

Bis(tri-tert-butylphosphine)palladium (0), N,N-dimethylacetamide, N,N-dicyclohexylmethylamine, tetrabutylammonium chloride;

Bis(tri-tert-butylphosphine)palladium (0), water/DMF (1:1), N,N-dicyclohexylmethylamine,

Bis(tri-tert-butylphosphine)palladium (0), water/DMF (1:1), N,N-dicyclohexylmethylamine, tetrabutylammonium chloride; and

Bis(tri-tert-butylphosphine)palladium (0), water/DMF (1:1), ammonia.

A leaving group L referred to hereinbefore or hereinafter includes, for example, chloro, bromo, iodo, —OSO2CF3, —COCl, —SO2Cl and —C(O)O—SO2Ry wherein Ry is aryl (such as phenyl) or substituted aryl (such as tolyl), particularly chloro, bromo, iodo, —OSO2CF3, and more particularly bromo.

The term “a group that is capable of conversion into a group Z” means that the group Y is selected from any functional group which can be converted, by carrying out one or more synthetic chemical steps, to form the group Z. Suitable groups Y which are capable of such conversion, and the synthetic chemical steps that can be used to carry out the conversion of Y into Z, are well known in the art, for example as described in standard works such as Contemporary Heterocyclic Chemistry by George R. Newkome and William W. Paudler, published by John Wiley & Sons, Inc., and Advanced Organic Chemistry by J. March, 4th and 5th Editions. Typical groups Y and synthetic chemical steps suitable for such conversion are illustrated, for example, in any of Schemes 1 to 5 or in the examples hereinafter, or by analogy therewith.

A group Y referred to hereinbefore or hereinafter includes, for example, hydroxy, chloro, bromo, iodo, amino, methylamino, benzylamino, methanesulfonylamino, N-benzylmethanesulfonylamino, RxSO2O— wherein Rx is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl), RyC(O)O— wherein Ry is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl). Particularly suitable groups Y include, for example, hydroxy, chloro, tosyloxy, amino, methylamino and methylsulfonylamino.

The term “aryl” herein includes, for example, a monocyclic or bicyclic aromatic hydrocarbon group that contains 6-12 atoms, such as phenyl, naphthyl, tetrahydronaphthyl, indenyl and indanyl, particularly phenyl. The term “substituted aryl” means an aryl group bearing one or more substituents, for example 1 to 3 substituents, more particularly 1 to 2 substituents. Suitable substituents include, for example, (1-4C)alkyl (such as methyl, ethyl or propyl), (1-4C)alkoxy (such as methoxy or ethoxy) and halogeno (such as chloro, bromo or iodo).

The terms “hydroxy protecting group” and “carboxy protecting group” referred to hereinbefore or hereinafter mean that the hydroxy or carboxy group is protected from reaction by forming a suitable derivative, such as a (1-4C)alkyl ester group. A hydroxy protecting group also includes, for example, tetrahydropyranyl, tert-butyl, methoxymethyl or a silyl radical, for example a silyl radical of the formula SiR3 wherein the R radicals can be the same or different and are selected from (1-6C)alkyl, phenyl and phenyl(1-4C)alkyl, in which latter two groups a phenyl group is unsubstituted or bears a halogeno, (1-4C)alkoxy or (1-4C)alkyl substituent. For example, a group SiR3, includes trimethylsilyl and tert-butyldimethylsilyl. Examples of suitable means of protection of hydroxy and carboxy groups (as well as means of formation and eventual deprotection), may be found in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York, 1999. Particular protecting groups hereinbefore or hereinafter for P1 taken together with P2, or P4 taken together with P5, or P5 taken together with P6, to form a 1,3-dihydroxy protecting group, include those described in EPA 0319845 and GB 2244705, which are included herein by reference. Particularly suitable 1,3-dihydroxy protecting groups include, for example, the groups (a), (b), (c) and (d) illustrated below


wherein Rw and Rx are independently (1-4C)alkyl, and Ry and Rz are independently (1-4C)alkyl, or one of Ry and Rz is (1-4C)alkyl and the other is hydrogen, or Ry and Rz taken together with the carbon atom to which they are attached form a cyclopentyl, cyclohexyl or cycloheptyl ring, and more particularly group (a) in which Ry and Rz are both methyl (i.e. an acetonide protecting group). Analogous protecting groups may also be used when P11 together with R4 forms a 1,3-dihydroxy protecting group.

Particularly suitable values for R1, R2, R3 and R4 include, for example, (1-4C)alkyl, such as methyl, ethyl, propyl, isopropyl, butyl and tert-butyl, especially the latter.

It will be appreciated that where more than one protecting group is removed after reacting a compound of the formula II with a compound of formula III, the protecting groups may be removed in any order which allows the compound of formula I to be obtained. It will also be appreciated that protecting groups and conditions for their removal may be chosen which allow for simultaneous removal of more than one protecting group. However it is preferred to carry out a final step under non-acidic conditions to avoid lactonisation of the compound of formula I.

A suitable pharmaceutically acceptable salt includes, for example, an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example, calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example with methylamine, ethylamine, dimethylamine, trimethylamine, morpholine, diethanolamine, tris(2-hydroxyethyl)amine and tris(hydroxymethyl)methylamine.

When A is a group (ii), the asymmetric reduction of the carbonyl group adjacent to the carbon-carbon double bond may be carried out, for example, using diethylmethoxyborane and sodium borohydride. The reaction may be carried out, for example, in an alcohol-organic solvent mixture. The alcohol may be selected from, for example, methanol, ethanol, propanol and butanol. The non-alcoholic organic solvent may be selected from, for example, acetonitrile, diethyl ether, tetrahydrofuran and dimethylformamide. A particularly suitable combination of solvents is, for example, methanol and tetrahydrofuran. The reaction is generally carried out at a temperature between −100° C. to 20° C., for example between −85° C. to −70° C., under cooling for 10 minutes to 20 hours, for example 30 minutes to 10 hours.

When A is a group (iv), the asymmetric hydration of the carbon-carbon double bond may be carried out, for example, using benzyl aldehyde in the presence of a base, such as potassium tert-butoxide or potassium hexamethyldisilazide, in a suitable solvent, such as tetrahydrofuran, and at a temperature in the range of −20° C. to +10° C., such as about 0° C., by analogy with the procedure described in J. Org. Chem., 1993, 58, 2446-2453 which is hereby incorporated herein by reference.

When A is a group (vi), the asymmetric hydration of the carbon-carbon double bond may be carried out, for example, using an appropriate alcohol, such as allyl alcohol, in the presence of a base, such as LiOH, or benzyl alcohol in the presence of a base, such as NaOH, followed by reduction using palladium on carbon or palladium hydroxide on carbon under acidic conditions, by analogy with the procedure described in WO 02/05519, which is hereby incorporated herein by reference.

When A is a group (vii), the asymmetric reduction of the carbon-carbon double bond adjacent to the group COOR4 may be carried out, for example, using similar conditions to those described above for the asymmetric reduction of the carbonyl group of A(ii).

Particular values of variable radicals or groups are as follows. Such values may be used where appropriate with any other of the values, definitions, claims or embodiments defined hereinbefore or hereinafter.

(1) in formula III, A is a group (i) wherein P1 and P2 together form an acetonide protecting group;

(2) in formula III, A is a group (i) wherein P1 and P2 are both hydrogen;

(3) in formula III, A is a group (ii) wherein P3 is a hydroxy protecting group

(4) in formula III, A is a group (ii) wherein P3 is hydrogen

(5) in formula III, A is a group (iii) wherein P4 to P7 are all hydroxy protecting groups

(6) in formula III, A is a group (iii) wherein P4 and P5 are both hydrogen and P6 and P7 are the same or different hydroxy protecting groups (such as (1-4C)alkyl groups, for example methyl or ethyl)

(7) in formula III, A is a group (iv) wherein P8 is a hydroxy protecting group (for example, trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldiphenylsilyl (TBDPS) or tert-butyldimethylsilyl (TBDMS))

(8) in formula III, A is a group (iv) wherein P8 is hydrogen

(9) in formula III, A is a group (v) wherein P9 is a hydroxy protecting group

(10) in formula III, A is a group (v) wherein P9 is hydrogen

(11) in formula III, A is a group (vi)

(12) in formula III, A is a group (vii) wherein P10 is hydrogen and P11 together with R4 is a 1,3-dihydroxy protecting group (for example, P11 together with R4 is an acetonide protecting group).

Starting materials of the formula II may be obtained, and conversion of a group Y into a group Z may be carried out, for example, as illustrated in the examples or as shown in Schemes 1 to 5 below, or by analogy therewith. It will be appreciated that when a compound of the formula II, wherein X is a group Y, is reacted with a compound of the formula III, then the intermediate obtained will include, for example, a compound as set out in Schemes 1 to 5 bearing the group -L, but in which the group -L is replaced by —CH═CH-A. The group Y may then be converted to the group CH3SO2N(CH3)— using one or more of the synthetic chemical steps illustrated in Schemes 1 to 5. In Schemes 1 to 5 and elsewhere herein, the following abbreviations are used:

EtOH=ethanol; NBS=N-bromosuccinimide; DMF=N,N-dimethylformamide; TEA=triethylamine; MeCN=acetonitrile; MsCl=mesyl chloride; TsCl=tosyl chloride; OTs=tosyloxy; THF=tetrahydrofuran; IPA=isopropanol; DCM=dichloromethane

Starting materials of formula III are already known or may be obtained, for example, using analogous processes to those used for obtaining the known compounds or structurally related compounds or as illustrated in the examples hereinafter, or by analogy therewith.

A compound of the formula III wherein A is a group (i) may be obtained, for example, as described in Org. Lett., 2003, Vol. 5, No. 23, 4385-4388 or SynLett, 2003, page 215-218, or Tetrahedron Letters, 2002, 43(10), 1851-1854, or by analogy therewith.

A compound of the formula III wherein A is a group (ii) may be obtained, for example, as disclosed in WO 03/04450 or by analogy therewith, or by analogy with the procedure described in JACS, 2000, page 8837, as follows:


or by reduction of the corresponding tricarbonyl compound, by analogy with the disclosures in J. Org. Chem. 1991, p. 5752; Eur. J. Org. Chem. 1999, p. 3421 and PCT. Int. Appl., 2001004336, as follows:

A compound of the formula III wherein A is a group (iii) may be obtained, for example, as follows:

A compound of the formula III wherein A is a group (iv) may be obtained, for example, as disclosed in Org. Lett., 2004, Vol. 6, No. 20, 3465-3467, or as follows:

A compound of the formula III wherein A is a group (v) may be obtained as described in SynLett, 2003, page 215-218.

A compound of the formula III wherein A is a group (vi) may be obtained by analogy with the procedure described in Tetrahedron Lett., 2003, page 8081.

A compound of the formula III wherein A is a group (vii) may be obtained, for example, as described in Synlett 1999, No. 9, 1435-1437, or by analogy therewith.

A further aspect of the present invention comprises the manufacture of a compound of the formula I or a pharmaceutically acceptable salt thereof comprising reaction of a compound of the formula II wherein X is N-(methyl)methylsulfonylamino and L is a leaving group, with a compound of the formula III wherein A is a group (i) as set out hereinbefore wherein P1 and P2 are independently selected from hydrogen or a hydroxy-protecting group, or P1 together with P2 form a 1,3-dihydroxy protecting group (and particularly wherein P1 and P2 form together a 1,3-dihydroxy protecting group, and especially wherein P1 and P2 complete a group (a) defined herein wherein Ry and Rz are both methyl, i.e. an acetonide protecting group) and R1 is a carboxy protecting group (such as (1-4C)alkyl and particularly tert-butyl), in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above; whereafter the protecting groups P1, P2 and R1 are removed in any order; whereafter when the product is obtained as the free acid, optionally forming a pharmaceutically acceptable salt of the compound of formula I, or when the product is obtained as a pharmaceutically acceptable salt, optionally converting the product to a different pharmaceutically acceptable salt. A further embodiment of this process comprises wherein a compound of the formula II is used in which X is N-(methyl)methylsulfonylamino and L is bromo. A further embodiment comprises wherein the latter compound is obtained from 5-bromo-2-hydroxy-4-(4-fluorophenyl)-6-isopropylpyrimidine, for example, by tosylation (such as by reaction with tosyl chloride) or chlorination (such as by reaction with phosphorus oxychloride), followed by reaction with N-methylmethanesulfonamide under basic conditions (for example in the presence of sodium hydride)). A further embodiment comprises wherein the 5-bromo-2-hydroxy-4-(4-fluorophenyl)-6-isopropylpyrimidine is obtained from 2-hydroxy-4-(4-fluorophenyl)-6-isopropylpyrimidine (for example by bromination with N-bromosuccinimide in DMF). A further embodiment comprises wherein the 2-hydroxy-4-(4-fluorophenyl)-6-isopropylpyrimidine is obtained from 1-(4-fluorophenyl)-4-methylpentane-1,3-dione (for example by reaction with urea under acidic conditions). A further embodiment comprises wherein the latter compound is obtained from an (1-4C)alkyl 4-fluorobenzoate (for example by reaction with 3-methyl-2-butanone in the presence of a base, such as potassium tert-butoxide). A further embodiment comprises wherein the protecting groups P1 and P2 are removed prior to removal of R1.

Conversion of a compound of formula I obtained in the free acid form into a pharmaceutically acceptable salt form may be carried out using any of the procedures well known in the art for the formation of salts from carboxylic acids. Conversion of a compound of the formula I obtained in a salt form may be converted into a different pharmaceutically acceptable salt using any of the procedures will known in the art for the interconversion of salts, for example, conversion of the sodium salt to the calcium salt by treatment with a water soluble calcium salt (such as calcium chloride or calcium acetate) under aqueous conditions (for example as disclosed in EP 521471, WO 00/49014, WO 04/52867 and WO 04/108691). It will be appreciated that the conversion of the free acid to a salt, or a salt to an alternative salt, may be carried out in situ, that is without prior isolation of the free acid or initial salt form, and may involve one or more conventional steps, for example as illustrated in the examples or in the references given above).

A further aspect of the present invention comprises a process for the manufacture of a compound of the formula IV


wherein P1 and P2 are independently hydroxy-protecting groups, or P1 together with P2 form a 1,3-dihydroxy protecting group, X is the group Z as defined above, and R1 is a carboxy protecting group, comprising reaction of a compound of the formula II, wherein X is the group Z as defined above and L is a leaving group, with a compound of the formula III in which A is a group (i) as set out hereinbefore wherein P1 and P2 are independently hydroxy-protecting groups, or P1 together with P2 form a 1,3-dihydroxy protecting group (and particularly wherein P1 and P2 form together a 1,3-dihydroxy protecting group, and especially wherein P1 and P2 complete a group (a) defined herein wherein Ry and Rz are both methyl, i.e. an acetonide protecting group), and R1 is a carboxy protecting group (such as (1-4C)alkyl and particularly tert-butyl), in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above. Further embodiments of this process are wherein the starting material of formula II is obtained as described above.

A further aspect of the present invention comprises a process for the manufacture of a compound of the formula IV wherein P1 and P2 are independently hydroxy-protecting groups, or P1 together with P2 form a 1,3-dihydroxy protecting group, X is a group Y as defined above, and R1 is a carboxy protecting group, comprising reaction of a compound of the formula II wherein X is a group Y as defined above and L is a leaving group, with a compound of the formula III wherein A is a group (i) as set out hereinbefore wherein P1 and P2 are independently hydroxy-protecting groups, or P1 together with P2 form a 1,3-dihydroxy protecting group (and particularly wherein P1 and P2 form together a 1,3-dihydroxy protecting group, and especially wherein P1 and P2 complete a group (a) defined herein wherein Ry and Rz are both methyl, i.e. an acetonide protecting group) and R1 is a carboxy protecting group (such as (1-4C)alkyl and particularly tert-butyl), in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above. Further separate independent embodiments of this process comprise the manufacture of compounds of the formula IV using a compound of the formula II wherein:

(i) X is hydroxy;

(ii) X is chloro;

(iii) X is amino;

(iv) X is methylamino;

(v) methanesulfonylamino; and

(vi) X is RxSO2O— wherein Rx is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl). The compounds of formula IV may be converted into a compound of formula I by removal of the protecting groups P1, P2 and R1 as described herein. In a particular embodiment P1 and P2 are removed before R1.

A further aspect of the present invention comprises a novel compound of the formula IV wherein X is a group Y as defined herein, P1 and P2 are independently hydroxy-protecting groups, or P1 together with P2 form a 1,3-dihydroxy protecting group, and R1 is a carboxy protecting group. In particular a compound of the formula IV wherein X is hydroxy, chloro, bromo, iodo, amino, methylamino, benzylamino, N-benzylmethanesulfonylamino, RxSO2O— wherein Rx is (1-6C)alkyl, aryl or substituted aryl, or RyC(O)O— wherein Ry is (1-6C)alkyl, aryl or substituted aryl, and P1 together with P2 are independently selected from hydrogen or a hydroxy-protecting group, or P1 together with P2 form a 1,3-dihydroxy protecting group and R1 is (1-4C)alkyl.

Within this group of compounds, further particular independent groups of compounds are those in which (i) X is hydroxy; (ii) X is chloro; (iii) X is amino; (iv) X is methylamino; (v) X is RxSO2O— wherein Rx is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl). Particular compounds of formula IV include, for example, wherein
(1) X is hydroxy, P1 and P2 taken together form an acetonide (—C(CH3)2—) protecting group and R1 is (1-4C)alkyl, especially tert-butyl;
(2) X is chloro, P1 and P2 taken together form an acetonide (—C(CH3)2—) protecting group and R1 is (1-4C)alkyl, especially tert-butyl;
(3) X is amino, P1 and P2 taken together form an acetonide (—C(CH3)2—) protecting group and R1 is (1-4C)alkyl, especially tert-butyl;
(4) X is methylamino, P1 and P2 taken together form an acetonide (—C(CH3)2—) protecting group and R1 is (1-4C)alkyl, especially tert-butyl; and
(5) X is tosyloxy, P1 and P2 taken together form an acetonide (—C(CH3)2—) protecting group and R1 is (1-4C)alkyl, especially tert-butyl

A further aspect of the present invention comprises the manufacture of a compound of the formula V


wherein P3 is hydrogen or a hydroxy-protecting group, X is the group Z as defined above, and R2 is a carboxy protecting group comprising reaction of a compound of the formula II wherein X is the group Z and L is a leaving group with a compound of the formula III in which A is a group (ii) as set out hereinbefore wherein P3 is a hydrogen or a hydroxy-protecting group and R2 is a carboxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above.

A further aspect of the present invention comprises the manufacture of a compound of the formula V wherein P3 is a hydroxy-protecting group, X is a group Y as defined above, and R2 is a carboxy protecting group, comprising reaction of a compound of the formula II wherein X is the group Y as defined herein and L is a leaving group, with a compound of the formula III in which A is a group (ii) as set out hereinbefore wherein P3 is a hydroxy-protecting group and R2 is a carboxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base. Further separate independent embodiments of this process comprise the manufacture of compounds of the formula V using a compound of the formula II wherein:

(i) X is hydroxy;

(ii) X is chloro;

(iii) X is amino;

(iv) X is methylamino;

(v) methanesulfonylamino; and

(vi) X is RxSO2O— wherein Rx is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl). The compounds of formula V may be converted into a compound of formula I by converting the group Y into the group Z, followed by carrying out in any order the steps of (1) asymmetric reduction of the carbonyl group adjacent to the carbon-carbon double bond; (2) removal of P3; and removal of the carboxy protecting group R2, as described herein. In a particular embodiment, the asymmetric reduction is carried out before removal of the protecting groups.

A further aspect of the present invention comprises novel compounds of the formula V.

A further aspect of the present invention comprises the manufacture of a compound of the formula VI


wherein P4, P5, P6 and P7 are independently hydroxy-protecting groups, or P4 together with P5 or P5 together with P6 form a 1,3-dihydroxy protecting group, and X is the group Z as defined herein, comprising reaction of a compound of the formula II as defined above, wherein X is the group Z as defined herein and L is a leaving group, with a compound of the formula III in which A is a group (iii) as set out hereinbefore wherein P4, P5, P6 and P7 are independently hydroxy-protecting groups, or P4 together with P5 or P5 together with P6 form a 1,3-dihydroxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above.

A further aspect of the present invention comprises the manufacture of a compound of the formula VI wherein P4, P5, P6 and P7 are independently hydroxy-protecting groups, or P4 together with P5 or P5 together with P6 form a 1,3-dihydroxy protecting group, and X is a group Y as defined herein, comprising reaction of a compound of the formula II, wherein X is a group Y as defined above and L is a leaving group, with a compound of the formula III in which A is a group (iii) as set out hereinbefore wherein P4, P5, P6 and P7 are independently hydroxy-protecting groups, or P4 together with P5 or P5 together with P6 form a 1,3-dihydroxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above. Further separate independent embodiments of this process comprise the manufacture of compounds of the formula VI using a compound of the formula II wherein:

(i) X is hydroxy;

(ii) X is chloro;

(iii) X is amino;

(iv) X is methylamino;

(v) methanesulfonylamino; and

(vi) X is RxSO2O— wherein Rx is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl). The compounds of formula VI may be converted into a compound of formula I by converting the group Y into the group Z, followed by carrying out in any order the removal of P4, P5, P6 and P7, as described herein.

A further aspect of the present invention comprises novel compounds of the formula VI.

A further aspect of the present invention comprises the manufacture of a compound of the formula VII


wherein P8 is a hydroxy-protecting group, X is the group Z as defined above, and R3 is a carboxy protecting group comprising reaction of a compound of the formula II wherein X is the group Z and L is a leaving group with a compound of the formula III in which A is a group (iv) as set out hereinbefore wherein P8 is a hydroxy-protecting group and R3 is a carboxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above.

A further aspect of the present invention comprises the manufacture of a compound of the formula VII wherein P8 is a hydroxy-protecting group, X is a group Y as defined above, and R3 is a carboxy protecting group comprising reaction of a compound of the formula II wherein X is a group Y and L is a leaving group with a compound of the formula III in which A is a group (iv) as set out hereinbefore wherein P8 is a hydroxy-protecting group and R3 is a carboxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base. Further separate independent embodiments of this process comprise the manufacture of compounds of the formula VII using a compound of the formula II wherein:

(i) X is hydroxy;

(ii) X is chloro;

(iii) X is amino;

(iv) X is methylamino;

(v) methanesulfonylamino; and

(vi) X is RxSO2O— wherein Rx is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl). The compounds of formula VII may be converted into a compound of formula I by converting the group Y into the group Z, followed by carrying out in any order the steps of (1) removal of P8; (2) asymmetric hydration of the carbon-carbon double bond adjacent to the ester group COOR3; and (3) removal of R3, as described herein. In a particular embodiment, the asymmetric hydration is carried out before P8 and R3 are removed.

A further aspect of the present invention comprises novel compounds of the formula VII.

A further aspect of the present invention comprises the manufacture of a compound of the formula VIII


wherein P9 is hydrogen or a hydroxy-protecting group and X is the group Z as defined above, comprising reaction of a compound of the formula II wherein X is the group Z and L is a leaving group with a compound of the formula III in which A is a group (v) as set out hereinbefore wherein P9 is a hydroxy-protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above.

A further aspect of the present invention comprises the manufacture of a compound of the formula VIII wherein P9 is hydrogen or a hydroxy-protecting group and X is a group Y as defined above, comprising reaction of a compound of the formula II wherein X is a group Y and L is a leaving group with a compound of the formula III in which A is a group (v) as set out hereinbefore wherein P9 is a hydroxy-protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base. Further separate independent embodiments of this process comprise the manufacture of compounds of the formula VIII using a compound of the formula II wherein:

(i) X is hydroxy;

(ii) X is chloro;

(iii) X is amino;

(iv) X is methylamino;

(v) methanesulfonylamino; and

(vi) X is RxSO2O— wherein Rx is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl). The compounds of formula VIII may be converted into a compound of formula I by converting the group Y into the group Z, followed by carrying out in any order the steps of (1) removal of the protecting group P9 if present and (2) ring opening by hydrolysis under basic conditions, as described herein. In a particular embodiment, P9 is a hydroxy protecting group.

A further aspect of the present invention comprises novel compounds of the formula VIII.

A further aspect of the present invention comprises the manufacture of a compound of the formula IX


wherein X is the group Z as defined above, comprising reaction of a compound of the formula II wherein X is the group Z and L is a leaving group with a compound of the formula III in which A is a group (vi) as set out hereinbefore, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above.

A further aspect of the present invention comprises the manufacture of a compound of the formula IX wherein X is a group Y as defined above, comprising reaction of a compound of the formula II wherein X is a group Y and L is a leaving group with a compound of the formula III in which A is a group (vi) as set out hereinbefore, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base. Further separate independent embodiments of this process comprise the manufacture of compounds of the formula IX using a compound of the formula II wherein:

(i) X is hydroxy;

(ii) X is chloro;

(iii) X is amino;

(iv) X is methylamino;

(v) methanesulfonylamino; and

(vi) X is RxSO2O— wherein Rx is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl). The compounds of formula IX may be converted into a compound of formula I by converting the group Y into the group Z, followed by carrying out in any order the steps of as (1) asymmetric hydration of the ring carbon-carbon double bond and (2) hydrolysis under basic conditions, as described herein. In a particular embodiment, the asymmetric hydration is carried out prior to hydrolysis.

A further aspect of the present invention comprises novel compounds of the formula IX.

A further aspect of the present invention comprises the manufacture of a compound of the formula X


wherein P10 and P11 are independently selected from hydrogen and a hydroxy protecting group, or P10 together with P11, or P11 together with R4, form a 1,3-dihydroxy protecting group; X is the group Z as defined herein; and R4 is a carboxy protecting group comprising reaction of a compound of the formula II as defined above, wherein X is the group Z as defined herein and L is a leaving group, with a compound of the formula III in which A is a group (vii) as set out hereinbefore wherein P10 and P11 are independently selected from hydrogen and a hydroxy protecting group, or P10 together with P11 form a 1,3-dihydroxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base as described above.

A further aspect of the present invention comprises the manufacture of a compound of the formula X wherein P10 and P11 are independently selected from hydrogen and a hydroxy protecting group, or P10 together with P11, or P11 together with R4, form a 1,3-dihydroxy protecting group; X is the group Y as defined herein; and R4 is a carboxy protecting group, comprising reaction of a compound of the formula II, wherein X is a group Y as defined above and L is a leaving group, with a compound of the formula III in which A is a group (vii) as set out hereinbefore wherein P10 and P11 are independently selected from hydrogen and a hydroxy protecting group, or P10 together with P11, or P11 together with R4, form a 1,3-dihydroxy protecting group, in the presence of a catalytically effective amount of a palladium catalyst and in the presence of a base. Further separate independent embodiments of this process comprise the manufacture of compounds of the formula X using a compound of the formula II wherein:

(i) X is hydroxy;

(ii) X is chloro;

(iii) X is amino;

(iv) X is methylamino;

(v) methanesulfonylamino; and

(vi) X is RxSO2O— wherein Rx is (1-6C)alkyl (such as methyl, ethyl or propyl), aryl (such as phenyl) or substituted aryl (such as tolyl). The compounds of formula X may be converted into a compound of formula I by converting the group Y into the group Z, followed by carrying out in any order the steps of (1) asymmetric reduction of the carbon-carbon adjacent to the group COOR4; (2) removal of the protecting groups, as described herein. In a particular embodiment, P11 is hydrogen.

A further aspect of the present invention comprises novel compounds of the formula X.

Further independent embodiments of the invention comprise any of the processes described above wherein the starting material of formula II is obtained from a compound of the formula XI.


by carrying out one or more chemical reactions, for example, as shown in any of Schemes 1 to 5, or as illustrated in the Examples hereinafter. In particular where the compound of formula II is 5-bromo-2-hydroxy-4-(4-fluorophenyl)-6-isopropylpyrimidine and is obtained from 2-hydroxy-4-(4-fluorophenyl)-6-isopropylpyrimidine (formula XI) by bromination, for example with N-bromosuccinimide in DMF.

A further aspect of the present invention comprises novel compounds of the formula II. Particular novel compounds of formula II include, for example,

  • 5-bromo-4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine;
  • 5-iodo-4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine;
  • 5-chloro-4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine;
  • 5-trifluoromethylsulfonyloxy-4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine;
  • 5-bromo-4-(4-fluorophenyl)-6-isopropyl-2-hydroxypyrimidine;
  • 5-iodo-4-(4-fluorophenyl)-6-isopropyl-2-hydroxypyrimidine;
  • 5-chloro-4-(4-fluorophenyl)-6-isopropyl-2-hydroxypyrimidine;
  • 5-trifluoromethylsulfonyloxy-4-(4-fluorophenyl)-6-isopropyl-2-hydroxypyrimidine;
  • 5-bromo-4-(4-fluorophenyl)-6-isopropyl-2-chloropyrimidine;
  • 5-iodo-4-(4-fluorophenyl)-6-isopropyl-2-chloropyrimidine;
  • 5-chloro-4-(4-fluorophenyl)-6-isopropyl-2-chloropyrimidine;
  • 5-trifluoromethylsulfonyloxy-4-(4-fluorophenyl)-6-isopropyl-2-chloropyrimidine;
  • 5-bromo-4-(4-fluorophenyl)-6-isopropyl-2-tosyloxypyrimidine;
  • 5-iodo-4-(4-fluorophenyl)-6-isopropyl-2-tosyloxypyrimidine;
  • 5-chloro-4-(4-fluorophenyl)-6-isopropyl-2-tosyloxypyrimidine;
  • 5-trifluoromethylsulfonyloxy-4-(4-fluorophenyl)-6-isopropyl-2-tosyloxypyrimidine;
  • 5-bromo-4-(4-fluorophenyl)-6-isopropyl-2-methylaminopyrimidine;
  • 5-iodo-4-(4-fluorophenyl)-6-isopropyl-2-methylaminopyrimidine;
  • 5-chloro-4-(4-fluorophenyl)-6-isopropyl-2-methylaminopyrimidine;
  • 5-trifluoromethylsulfonyloxy-4-(4-fluorophenyl)-6-isopropyl-2-methylaminopyrimidine;
  • 5-bromo-4-(4-fluorophenyl)-6-isopropyl-2-methanesulfonylaminopyrimidine;
  • 5-iodo-4-(4-fluorophenyl)-6-isopropyl-2-methanesulfonylaminopyrimidine;
  • 5-chloro-4-(4-fluorophenyl)-6-isopropyl-2-methanesulfonylaminopyrimidine;
  • 5-trifluoromethylsulfonyloxy-4-(4-fluorophenyl)-6-isopropyl-2-methanesulfonylaminopyrimidine;
  • 5-bromo-4-(4-fluorophenyl)-6-isopropyl-2-aminopyrimidine;
  • 5-iodo-4-(4-fluorophenyl)-6-isopropyl-2-aminopyrimidine;
  • 5-chloro-4-(4-fluorophenyl)-6-isopropyl-2-aminopyrimidine; and
  • 5-trifluoromethylsulfonyloxy-4-(4-fluorophenyl)-6-isopropyl-2-aminopyrimidine; and the salts thereof.

A further aspect of the present invention comprises novel starting materials for obtaining compounds of the formula II including, for example, 2-hydroxy-4-(4-fluorophenyl)-6-isopropylpyrimidine (formula XI).

A still further aspect of the invention comprises a process for the production of 2-hydroxy-4-(4-fluorophenyl)-6-isopropylpyrimidine said process comprising

a) reaction of ethyl-4-fluorobenzoate with 3-methyl-2-butanone in toluene to give 1-(4-fluorophenyl)-4-methylpentane-1,3-dione as a solution in toluene; and

b) reaction of said solution in toluene with urea and hydrogen chloride in isopropanol.

Advantageously, the above process, which starts from simple starting materials, efficiently avoids the need to isolate the intermediate 1-(4-fluorophenyl)-4-methylpentane-1,3-dione because toluene is present as a solvent in both steps. The second step is generally carried out at elevated temperatures, for example at about 80°. Suitable conditions for carrying out this process are as illustrated in the accompanying examples.

The invention is further illustrated, but not limited by, the following Examples.

EXAMPLE 1

A mixture of N-(5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (1.00 g, 2.50 mmol), bis-tri-tert-butylphosphine palladium (0) (131 mg, 0.250 mmol), tert-butyl 2-((4R,6S)-2,2-dimethyl-6-vinyl-1,3-dioxan-4-yl)acetate (640 mg, 2.50 mmol), water (5 mL), N,N-dicyclohexylmethylamine (0.530 mL, 2.50 mmol), and N,N-dimethylformamide (5 mL) was heated and stirred at 50° C. under nitrogen for four days. The mixture was then diluted with ethyl acetate (11 mL), water (10 mL), and acetic acid (0.2 mL). The organic phase was separated and the aqueous phase was extracted with ethyl acetate (5 mL). The combined organic phases were washed with water (10 mL), then brine (10 mL), and concentrated in vacuo to give a yellow oil containing some solids. This material was adsorbed onto silica gel through dissolution in ethyl acetate, then purified by flash chromatography (5% ethyl acetate in isohexane gradually increasing to 20% ethyl acetate in hexane, silica column 25 mm in diameter and 250 mm in height) to yield tert-butyl 2-((4R,6S)-6-((E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate of the formula


(hereinafter referred to as BEM) as a white solid (204 mg). The isolated product was spectroscopically identical to the compound BEM described in International Patent Application, Publication No. WO 00/49014.

The compound BEM can then be converted into rosuvastatin calcium as described in International Patent Application, Publication No. WO 00/49014 (incorporated herein in full by reference) as follows:—

A mixture of BEM (5.0 g) and acetonitrile (35 ml) was stirred under an inert atmosphere at 40° C. 0.02M hydrochloric acid (9.5 ml) was added over 30 minutes to the resultant solution, maintaining the temperature at 35° C. to 42° C. The mixture was stirred at 40° C. for 3 hours then cooled to 25° C. 1.0M sodium hydroxide solution (9.5 ml) was added with stirring at 25° C. and the mixture was stirred for an additional one hour at 25° C. Sodium chloride (4.7 g) was added and the mixture was cooled to −5° C. over one hour. Sufficient of a solution of 1M hydrochloric acid (9.5 ml) and sodium chloride (2.4 g) was added at −5° C. to achieve a pH of 3.4 to 4.0 and the mixture stirred at this temperature for 5 minutes. The mixture was allowed to settle for 10 minutes at −5° C. to give two layers. The lower layer was separated and discarded. Acetonitrile (65 ml) at −5° C. was added to the remaining solution and the mixture was filtered through a filter agent. 40% methylamine solution in water (1.1 ml) was added at −5° C. and the mixture was warmed to 30° C. over 40 minutes and maintained at this temperature for 90 minutes. The mixture was then cooled to 0° C. over 40 minutes and maintained at this temperature for 90 minutes. The resultant solid was collected by filtration and washed with acetonitrile (2×12 ml). The solid, which is the methylamine salt of the compound of formula IV (R1=MeNH3 +), was dried under vacuum at 35° C. (3.87 g). 8% w/w aqueous sodium hydroxide (5.44 ml) was added to a stirred mixture of the methylamine salt (6.0 g) in degassed water (30 ml) at 20° C. and the mixture was stirred for one hour. The mixture was filtered and concentrated under reduced pressure at 40° C. until 24 ml of distillate collected. Water (24 ml) was added and the mixture again concentrated under reduced pressure at 40° C. until 24 ml of distillate collected. Water (30 ml) was added and a solution of calcium chloride dihydrate (1.03 g) in water (6 ml) was added dropwise at 20° C. The mixture was stirred for 45 minutes and the resultant solid filtered. The solid was washed with water (36 ml) and dried under vacuum at 40° C. to give the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid.

Alternatively the compound BEM may be converted into rosuvastatin calcium as described in International Patent Application WO 04/108691 (incorporated herein in full by reference) as follows: BEM (20.0 g) was dissolved in acetonitrile (140 ml) at 40° C., then cooled to 35° C. before gradual addition of hydrochloric acid (0.02M, 35 ml) at 35° C. The resulting solution was stirred at 35° C. until the reaction was complete then cooled to 25° C. Sodium hydroxide (1.0M, 38 ml) was added at 25° C. and the resulting mixture stirred at this temperature until the reaction was complete. Aqueous hydrochloric acid (1M) was added to adjust the pH of the solution to pH9. The solution was distilled under reduced pressure (52 mBar, ≦40° C.) until approximately 100 ml of acetonitrile/water had been removed. Water (100 ml) was added and distillation continued until a further 100 ml of acetonitrile/water had been removed. The resulting mixture was filtered through a filter pad, the filter washed with water (30 ml) and the filtrates heated to 40° C. before addition of a solution of calcium chloride dihydrate (3.07 g) in water (29.5 ml) over 20 min, maintaining the reaction mixture at 38-41° C.

The reaction mixture was stirred for a further 15 min at 40° C., then cooled to 20° C. and stirred at this temperature for a further 15 min. The resulting suspension was filtered, washed with water (3×50 ml) and dried to give (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt (15.8 g, 84% yield);

and as follows:

BEM (20.0 g) was dissolved in acetonitrile (140 ml) at 40° C., then cooled to 35° C. before gradual addition of hydrochloric acid (0.02M, 35 ml) at 35° C. The resulting solution was stirred at 35° C. until the reaction was complete then cooled to 25° C. Further acetonitrile (8 ml) was added before sodium hydroxide (1.0M, 38 ml) was added at 25° C. and the resulting mixture stirred at this temperature until the reaction was complete. Aqueous hydrochloric acid (0.1M) was added to adjust the pH of the solution to approximately pH10.5. Water was added so that the combined volume of water and hydrochloric acid (0.1M) (from the previous pH adjustment step) added was 100 ml. Toluene (125 ml) was then added and the mixture stirred at 40° C. for 30 minutes before it was allowed to settle for 1 hour at 40° C. The aqueous phase was then separated from the organic phase at 40° C. The aqueous phase was distilled under reduced pressure (53 mBar, ≦40° C.) until the volume was reduced to 135 ml. The resulting aqueous solution was filtered through a filter pad and the filter washed with water and combined with the aqueous reaction solution, such that the total volume of the resulting aqueous solution was 170 ml. This solution was heated to 40° C. before addition of a solution of calcium chloride di-hydrate (3.05 g) in water (29.5 ml) over 20 min, maintaining the reaction mixture at 38-41° C.

The reaction mixture was stirred for a further 15 min at 40° C., then cooled to 20° C. and stirred at this temperature for a further 15 min. The resulting suspension was filtered, washed with water (3×53 ml) and dried to give (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt (14.7 g@100% strength, 85% yield).

1HNMR δ: 1.21 (d+d, 6H) 1.32 (dt, 1H) 1.51 (dt, 1H) 2.00 (dd, 1H) 2.14 (dd, 1H) 3.42 (spt, 1H)* 3.45 (s, 3H) 3.54 (s, 3H) 3.77 (m, 1H) 4.21 (q, 1H) 5.53 (dd, 1H) 6.51 (dd, 1H) 7.27 (t, 2H) 7.71 (dd, 2H)

*partially obscured

[The 1H NMR was carried out as a 3% w/v solution in d6 DMSO (where d5 DMSO=2.51δ)].

The starting material N-(5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide was obtained as follows:

(i) A 5M to 6M solution of hydrogen chloride in isopropanol (38 mL, 194 mmoles) was added to a stirred mixture of urea (7.78 g, 129.6 mmoles) and 1-(4-fluorophenyl)-4-methylpentane-1,3-dione (8.43 g, 32.4 mmoles) in ethanol (49 mL). The reaction mixture was refluxed for 40 hours and then cooled to −6° C. The resultant precipitate was collected by filtration and washed with diethyl ether (20 mL). The solid was added to water (60 mL) and saturated aqueous sodium bicarbonate solution (10 mL). Further solid sodium bicarbonate (16.4 g, 195 mmoles) was added portionwise. The mixture was diluted with acetone (40 mL) and ethyl acetate (80 mL). The organic phase was separated and aqueous phase was extracted 2:1 ethyl acetate/acetone (3×120 mL). The organic phases were combined, washed with brine (30 mL), dried with anhydrous magnesium sulfate and concentrated in vacuo to yield 4.8 g of 4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol (64% yield); 1H NMR (400 MHz) (CDCl3) δ TMS: 1.41 (6H, d, J=6.90 Hz), 3.08 (1H, m), 6.69 (1H, s), 7.17 (2H, dd, J=8.60 Hz, J=8.60 Hz), 8.14 (2H, dd, J=6.65 Hz, J=6.65 Hz), 13.57 (1H, br. s). Mp: 215-217° C. HRMS calculated for C13H13N2OF. 232.1012, found 232.0963; used in subsequent reaction without further purification.
(ii) N-Bromosuccinimide (3.504 g, 19.69 mmoles) was added to suspension of 4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol (4.573 g, 19.69 mmoles) in DMF (30 mL) at −8.5° C. The mixture was stirred for 10 minutes and the reaction mixture was allowed to warm to ambient temperature. The mixture was stirred for 4 hours and then diluted with ethyl acetate (80 mL), toluene (20 mL), and water (100 mL). The organic phase was separated, and the aqueous phase extracted with 4:1 ethyl acetate/toluene (2×100 mL). The organic phases were combined and diluted with acetone (100 mL). The solution was washed with brine (75 mL), followed by saturated aqueous sodium bicarbonate (40 mL), and then concentrated in vacuo (with 3×40 mL toluene azeotropes) to yield 6.031 g of 5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol (98% yield); 1H NMR (400 MHz) (CDCl3) 6 TMS: 1.39 (6H, d, J=6.90 Hz), 3.57 (1H, m), 7.16 (2H, dd, J=8.60 Hz, J=8.60 Hz), 7.66 (2H, dd, J=8.70 Hz, J=5.40 Hz). Mp: Decomposes at 199° C. HRMS calculated for C13H12N2OFBr 310.0117, found 310.0116; used in subsequent reaction without further purification.
(iii) Phosphoryl chloride (5.00 mL, 53.8 mmoles) was added to 5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol (5.027 g, 15.28 mmoles) and the reaction mixture was heated to an internal temperature of 90° C. The mixture was then stirred for 150 minutes at this temperature, then allowed to cool to 25° C. The reaction mixture was quenched by dropwise addition (with 30 mL of EtOAc rinses) into a stirred mixture of ice (60 g), water (40 mL), and sodium bicarbonate (10 g). After completion of the addition, sodium bicarbonate (13 g) added to assure neutrality. The mixture was then extracted with ethyl acetate (4×70 mL). The organic phases were combined and dried with anhydrous magnesium sulphate. The solution was filtered through a pad of diatomaceous earth, and concentrated in vacuo to yield 5-bromo-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine (4.98 g, 99% yield); 1H NMR (400 MHz) (CDCl3) 6 TMS: 1.34 (6H, d, J=6.70 Hz), 3.64 (1H, m), 7.17 (2H, dd, J=8.65 Hz, J=8.65 Hz), 7.73 (2H, dd, J=8.80 Hz, J=5.20 Hz). Mp: 99-101° C. HRMS calculated for C13H11N2FClBr 327.9778, found 327.9752; used in subsequent reaction without further purification.
(iv) Sodium hydride (1.20 g, 30.0 mmol, 60% suspension in mineral oil) was washed with hexane (2×10 mL), and DMF (50 mL) was then added, followed by 5-bromo-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine (4.944 g, 15.0 mmoles). The resulting suspension was cooled to −7° C. and N-methylmethanesulfonamide (2.585 g, 22.5 mmoles) was added, washed in with DMF (10 mL). The mixture was stirred for 17.5 hours, then diluted with ethyl acetate (80 mL), toluene (100 mL), and water (120 mL). The organic phase was separated, and the aqueous phase was extracted with a mixture of ethyl acetate (20 mL) and toluene (30 mL). The organic phases were combined, washed with water (2×40 mL) and then brine (20 mL), and dried over anhydrous magnesium sulphate. The solution was concentrated in vacuo (with two 20 mL hexane azeotropes) to yield N-(5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (5.50 g, 91% yield); 1H NMR (400 MHz) (CDCl3) δ TMS: 1.32 (6H, d, J=6.60 Hz), 3.49 (3H, s), 3.55 (3H, s), 3.63 (1H, m), 7.16 (2H, dd, J=8.65 Hz, J=8.65 Hz), 7.77 (2H, dd, J=8.70 Hz, J=5.30 Hz). Mp: 122-125° C. HRMS calculated for C13H17N3O2FSBr 401.0209, found 401.0225; used in subsequent reaction without further purification.

An alternative route to N-(5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide is as follows:

4-(4-Fluorophenyl)-6-isopropylpyrimidin-2-ol

The reactor used for this experiment was thoroughly dried by carrying out a toluene distillation prior to use. Fresh toluene (100 mL) and potassium tert-butoxide (7.50 g, 64.8 mmol) were charged to the vessel and stirred to form a slurry. The mixture was cooled to −9° C. and 3-methyl-2-butanone (3.63 g, 41.7 mmol) added. The mixture was warmed to −5° C. and stirred for 30 mins. Ethyl-4-fluorobenzoate (6.25 g, 36.8 mmol) was dissolved in toluene (4 mL) and added via a syringe followed by a small toluene (1 ml) line wash. The mixture was stirred for 10 minutes at 0° C., warmed to 10° C., and then stirred at this temperature overnight. The mobile slurry was warmed to 25° C. and acetic acid (4.4 mL) added, followed by water (37.5 mL). The mixture was stirred thoroughly for 5 minutes and then allowed to stand. The lower phase was run off and discarded. A 5% sodium bicarbonate solution (16 mL) was charged to the upper phase, stirred for 5 minutes and then allowed to stand. The lower aqueous layer was run off and the upper organic phase washed twice with water (5 mL).

The remaining toluene solution was dried by azeotropic distillation (refluxing with Dean-Stark trap in place) and the solution cooled to 60° C. Urea (5.1 g, 84.9 mmol) and isopropanol (20 mL) were charged and stirred vigorously during the addition of hydrochloric acid (5 to 6 M in isopropanol, 32.3 mL, 183 mmol). The solution was heated to 80° C. and stirred for 48.5 hours before charging more hydrochloric acid in isopropanol (2 mL, 11 mmol). After a total of 112 hours at 80° C., the mixture was cooled to 60° C. and water (50 mL) added. After stirring for 15 minutes, the mixture was allowed to stand and the lower aqueous phase run off and retained. The aqueous phase was stirred and sodium hydrogen carbonate (6.9 g) added portion wise until pH=7. The product crystallised from solution and was then cooled to 20° C. The solid was filtered off and washed twice with water (20 mL) and dried in a vacuum oven at 50° C. overnight. 4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol (4.92 g) was isolated as a white powder in 56% overall yield; 1H NMR (400 MHz; CDCl3) δ: 1.41 (6H, d), 3.08 (1H, m), 6.69 (1H, s), 7.17 (2H, dd), 8.14 (2H, dd), 13.57 (1H, br. s). Mp: 215-217° C. HRMS calculated for C13H13N2OF 232.1012, found 232.0963; used in subsequent reaction without further purification.

5-Bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol

4-(4-Fluorophenyl)-6-isopropylpyrimidin-2-ol (8.00 g, 34.1 mmol) was charged to a reactor followed by DMF (100 mL). The suspension was stirred, cooled to −3° C. and N-bromosuccinimide (6.25 g, 34.8 mmol) added. The reaction mixture was warmed to 20° C. and stirred overnight. Water (100 mL) was charged to the reaction mixture and the crystalline mixture stirred for 1 hour before filtering off. The isolated solid was washed twice with water (25 mL) and the solid dried in a vacuum oven at 50° C. 5-Bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol (10.45 g, 97% yield) was obtained as a white solid;

1H NMR (400 MHz; CDCl3) δ: 1.39 (6H, d), 3.57 (1H, m), 7.16 (2H, dd), 7.66 (2H, dd). Mp: Decomposes at 199° C. HRMS calculated for C13H12N2OFBr 310.0117, found 310.0116; used in subsequent reaction without further purification.

N-(5-Bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide

5-Bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol (62.2 g, 199 mmol), potassium carbonate (35.83 g, 259 mmol) and butyl acetate (435.4 mL) were charged to a 2 L multi-neck flask and stirred/heated to 42° C. p-Toluenesulfonyl chloride (41.83 g, 219 mmol) was then added in portions over 50 minutes, maintaining the temperature at ≦45° C. The reaction was stirred at this temp for 2.5 hours, at which point LCMS showed only the desired intermediate (MH+=467) present. Potassium carbonate (41.25 g, 299 mmol) and butyl acetate (186.6 mL) were then added and reaction heated to 120° C. Once at this temperature N-methylmethanesulfonamide (28.21 g, 259 mmol) was added over 30 mins. The reaction was held at this temperature for 18 hours, then butyl acetate (330 mL) and water (412 mL) were added, reducing the reaction temperature to 75° C. Stirring was continued at this temperature for 20 minutes, then the reaction mixture was transferred to a separating funnel, and allowed to stand for 10 mins to separate. The aqueous layer was separated off and re-extracted with butyl acetate (250 mL) by stirring at 60° C. for 15 mins. The organic layers were combined and 1 M aqueous NaOH (330 mL) added. This mixture was stirred at 60° C. for 20 minutes, then the lower aqueous phase separated off. The organic layer was concentrated in vacuo to 20% original volume, then allowed to cool and crystallize. The crude solid was isolated by filtration (50.5 g slightly damp), and this material recrystallized from methanol (500 mL), filtered and dried at 50° C. to constant weight to give the title compound (30.54 g, 38% yield) as a white crystalline solid.

1H NMR (400 MHz; CDCl3) δ: 1.32 (6H, d), 3.49 (3H, s), 3.55 (3H, s), 3.63 (1H, m), 7.16 (2H, dd), 7.77 (2H, dd). Mp: 122-125° C. HRMS calculated for C13H17N3O2FSBr 401.0209, found 401.0225.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US480621Apr 5, 1892Aug 9, 1892 Oiler for handsaws
US4613610Jun 6, 1985Sep 23, 1986Sandoz Pharmaceuticals Corp.Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4625039Dec 21, 1983Nov 25, 1986Sandoz Pharm. Corp.4-trisubstituted silyl protected hydroxy-6-oxo-tetrahydropyran-2-yl-aldehyde intermediates
US4645858Oct 10, 1985Feb 24, 1987G. D. Searle & Co.Pentanedioic acid derivatives
US4650890Jul 26, 1985Mar 17, 1987Sandoz Corp.Preparation of olefinic compounds and intermediates thereof
US4677211Jul 26, 1985Jun 30, 1987Sandoz Pharmaceuticals Corp.Preparation of lactones
US4957971Dec 6, 1988Sep 18, 1990Warner-Lambert CompanyTrans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4968681Nov 15, 1988Nov 6, 1990Bayer AktiengesellschaftSubstituted hydroxylamines
US4970313Dec 6, 1988Nov 13, 1990Hoechst AktiengesellschaftOptically active 3-demethylmevalonic acid derivatives, and intermediates
US4977279Nov 20, 1989Dec 11, 1990Hoechst AktiengesellschaftProcess for the preparation of optically active 3-demethylmevalonic acid derivatives, and intermediates
US5079347Dec 6, 1988Jan 7, 1992Hoechst AktiengesellschaftWater-soluble disazo compounds having a halogen-substituted s-triazinyl radical, suitable as dyestuffs
US5102893Jun 19, 1990Apr 7, 1992Warner-Lambert CompanyTrans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5260440Jun 12, 1992Nov 9, 1993Shionogi Seiyaku Kabushiki KaishaPyrimidine derivatives
US5278313Mar 27, 1992Jan 11, 1994E. R. Squibb & Sons, Inc.Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
US5399722Jun 30, 1993Mar 21, 1995Hoechst AktiengesellschaftProcess for preparing tert-butyl (3R,5S)-6-hydroxy-3,5--O--isopropylidene-3,5-dihydroxyhexanoate
US5594153Jul 5, 1995Jan 14, 1997E. R. Squibb & Sons, Inc.Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
US5681957May 3, 1996Oct 28, 1997Bayer AktiengesellschaftProcess for the preparation of substituted 2-fluoro-pyrimidines
US6278001Nov 12, 1996Aug 21, 2001L'oréalMethod for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
US6331641Dec 10, 1999Dec 18, 2001Kaneka CorporationProcess for producing simvastatin
US6579984Jun 30, 2000Jun 17, 2003Lonza AgProcess for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
US6689591Jan 7, 2002Feb 10, 2004Forschungszentrum Jülich GmbHMethod of reducing keto-carboxylic acids and their esters
US6784171Jul 2, 2003Aug 31, 2004AstrazenecaProcess for the production of tert-butyl (E)-(6-[2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)-2, 2-dimethyl[1, 3]dioxan-4-yl)acetate
US6844437Feb 15, 2000Jan 18, 2005Astrazeneca AbProcess for the production of tert-butyl (E)-(6-[2-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsufonyl)amino]pyrimidin-5-yl]vinyl]4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate
US6855716Dec 26, 2001Feb 15, 2005Ajinomoto Co., Inc.Dihydropyrimidine compounds and compositions containing the same
US6870059Jul 12, 2001Mar 22, 2005Astrazeneca Uk Ltd.Process for the preparation of 2-(6-substituted-1,-3-dioxane-4-yl)acetic acid derivatives
US7157255May 1, 2001Jan 2, 2007Astrazeneca Uk LimitedProcess for the preparation of dihydroxy esters and derivatives thereof
US7199140Jun 24, 2002Apr 3, 2007Astrazeneca AbVinyl phenyl derivatives as GLK activators
US7304156Jul 12, 2002Dec 4, 2007Astrazeneca Uk LimitedPreparation of aminopyrimidine compounds
US7416865Apr 27, 2006Aug 26, 2008Astrazeneca Uk LimitedProcess for the preparation of dihydroxy esters and derivatives thereof
US7442811Jun 12, 2003Oct 28, 2008Astrazeneca Uk LimitedProcess for the preparation of dioxane acetic acid esters
US7511140Aug 7, 2003Mar 31, 2009Astrazeneca AbProcess for preparing the calcium salt of rosuvastatin
US7524955Dec 9, 2003Apr 28, 2009Astrazeneca Uk LimitedProcess for the preparation of pyrimidine compounds
US7642363Feb 7, 2005Jan 5, 2010Astrazeneca Uk Ltd.Process for the preparation of 2-(6-substituted-1,3-dioxane-4-YL) acetic acid derivatives
US7718812Dec 9, 2002May 18, 2010Astrazeneca Uk LimitedProcess for the preparation of 2-(6-substituted-1,3-dioxane-4-yl) acetic acid derivates
US7732171Jul 23, 2008Jun 8, 2010Astrazeneca Uk LimitedProcess for the preparation of dihydroxy esters and derivatives thereof
US7816528Nov 1, 2007Oct 19, 2010Astrazeneca Uk LimitedPreparation of aminopyrimidine compounds
US20030018199May 30, 2002Jan 23, 2003Brodfuehrer Paul R.Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors
US20050124639Dec 3, 2004Jun 9, 2005Narendra JoshiProcess for the preparation of pyrimidine derivatives
US20060293355Sep 8, 2004Dec 28, 2006Booth Rebecca JCrystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s)-3, 5-dihydroxyhept-6-enoicacid] calcium salt
US20070093660Nov 9, 2004Apr 26, 2007Vitali TararovMethod for the production of statins
US20070105882Sep 17, 2004May 10, 2007Black Simon NPolymorphic forms of a known antihyperlipemic agent
US20070255060Oct 22, 2004Nov 1, 2007Tetsuo OkadaProcess for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof
US20080188657Nov 30, 2007Aug 7, 2008Astrazeneca Uk LimitedChemical process
US20080221323Jun 3, 2004Sep 11, 2008Jeffrey Norman CrabbProduction of Rosuvastatin Calcium Salt
US20090264654Mar 16, 2009Oct 22, 2009Astrazeneca Uk LimitedProcess for the preparation of pyrimidine compounds
US20090286819Feb 13, 2009Nov 19, 2009Astrazeneca AbProcess for Preparing the Calcium Salt of Rosuvastatin
US20100222373Nov 10, 2009Sep 2, 2010AstarZeneca UK LimitedCrystalline Form of Bis [(E)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2-[methyl(methyl-sulfonyl)amino] pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] Calcium Salt
US20100228028Jul 3, 2006Sep 9, 2010Michael ButtersProcesses for the manufacture of rosuvastatin and intermediates
EP0252476A2Jul 6, 1987Jan 13, 1988Warner-Lambert CompanyTrans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof
EP0319845A2Dec 1, 1988Jun 14, 1989Hoechst AktiengesellschaftWater soluble disazo compounds, process for their preparation and their use as dyestuffs
EP0319847A2Dec 1, 1988Jun 14, 1989Hoechst AktiengesellschaftMethod for the preparation of optically active 3-desmethylmevalonic acid derivatives and intermediate compounds
EP0521471A1Jun 30, 1992Jan 7, 1993Shionogi Seiyaku Kabushiki KaishaPyrimidine derivatives as HMG-CoA reductase inhibitors
GB2244705A Title not available
JPH06256318A Title not available
WO1990003973A1Mar 6, 1989Apr 19, 1990Sandoz AgPyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
WO1992001675A2Jul 18, 1991Feb 6, 1992Rhone-Poulenc Rorer S.A.Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene b4 antagonist activity, their preparation and use in pharmaceutical compositions
WO1993008823A1Nov 6, 1991May 13, 1993Tanabe Seiyaku Co., Ltd.Guanidinyl and related cell adhesion modulation compounds
WO1996014846A1Nov 16, 1995May 23, 1996Synaptic Pharmaceutical CorporationDihydropyrimidines and uses thereof
WO1997019917A1Nov 12, 1996Jun 5, 1997L'orealMETHOD FOR PREPARING (+)COMPACTIN AND (+)MEVINOLIN ANALOG COMPOUNDS HAVING A β-HYDROXY-δ-LACTONE GROUPING
WO1997021687A1Dec 12, 1996Jun 19, 1997Merck & Co., Inc.Process for making dihydropyrimidinones
WO1999007695A2Jul 31, 1998Feb 18, 1999Merck & Co., Inc.ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST
WO2000049014A1Feb 15, 2000Aug 24, 2000Astrazeneca AbProcess for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
WO2000078730A1Jun 22, 2000Dec 28, 2000Ajinomoto Co., Inc.Novel dihydropyrimidine derivatives
WO2001004100A1Jun 30, 2000Jan 18, 2001Lonza AgProcess for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
WO2001004336A1Jul 5, 2000Jan 18, 2001Forschungszentrum Jülich GmbHMethod of reducing keto-carboxylic acids and their esters
WO2001060804A1Feb 12, 2001Aug 23, 2001Astrazeneca AbCrystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2001072706A1Mar 28, 2000Oct 4, 2001Biocon India LimitedSynthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2001085702A1May 4, 2001Nov 15, 2001Astrazeneca Ab(e)-7(4-fluorophenyl)-6isopropyl2-mesylaminopyrimidin-5-y)-(3r,5s)-dihydroxyhept-6-enoic acid.
WO2001085975A1May 1, 2001Nov 15, 2001Avecia LimitedProcess for the preparation of dihydroxy esters and derivatives thereof
WO2002005519A2Jul 6, 2001Jan 17, 2002Motorola, Inc., A Corporation Of The State Of DelawareMethod and apparatus for storing a message for playback during a user-initiated emergency telephone call from a wireless device
WO2002006266A1Jul 12, 2001Jan 24, 2002Dsm N.V.Process for the preparation of 2-(6-substituted-1,3-dioxane-4-yl)acetic acid derivatives
WO2002038551A1Nov 6, 2001May 16, 2002F. Hoffman-La Roche AgPyrimidine derivatives and their use as neuropeptide y receptor ligands
WO2003004450A1Jul 2, 2002Jan 16, 2003Ciba Specialty Chemicals Holding Inc.Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
WO2003006439A1Jul 12, 2002Jan 23, 2003Astrazeneca Uk LimitedPreparation of aminopyrimidine compounds
WO2003018555A1Aug 13, 2002Mar 6, 2003Ciba Speciality Chemicals Holding Inc.Process for the preparation of indole derivatives
WO2003059901A1Dec 9, 2002Jul 24, 2003Astrazeneca Uk LtdProcess for the preparation of 2-(6-substituted-1,3-dioxane-4-yl) acetic acid derivates
WO2003064382A2Jan 27, 2003Aug 7, 2003Novartis AgProcess for the manufacture of organic compounds
WO2003087112A1Apr 9, 2003Oct 23, 2003Cls Laboratories, Inc.Chiral intermediate and process for the production thereof
WO2003106447A1Jun 12, 2003Dec 24, 2003Dsm Ip Assests B.V.Process for the preparation of dioxane acetic acid esters
WO2004014872A1Aug 7, 2003Feb 19, 2004Astrazeneca Uk LimitedProcess for preparing the calcium salt of rosuvastatin
WO2004052867A1Dec 10, 2002Jun 24, 2004Ranbaxy Laboratories LimitedProcess for the preparation of rosuvastatin
WO2004054986A2Dec 9, 2003Jul 1, 2004Astrazeneca Uk LimitedProcess for the preparation of pyrimidine compounds
WO2004103977A2May 12, 2004Dec 2, 2004Ciba Specialty Chemicals Holding Inc.Process for the preparation of pyrimidine derivatives
WO2004108691A1Jun 3, 2004Dec 16, 2004Astrazeneca Uk LimitedImproved production of rosuvastatin calcium salt
WO2005023779A1Sep 8, 2004Mar 17, 2005Astrazeneca Uk LimitedCrystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6 -enoicacid] calcium salt
WO2005028450A1Sep 17, 2004Mar 31, 2005Astrazeneca Uk LimitedPolymorphic forms of a known antihyperlipemic agent
WO2005042522A1Oct 22, 2004May 12, 2005Astrazeneca Uk LimitedProcess for the manufacture of the calcium salt of rosuvatatin (e)-7-`4- (4-fluorophenyl) -6-isopropyl-2-`methyl (methylsulfonyl) amino ! pyrimidin -5-yl ! (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
WO2005047276A2Nov 9, 2004May 26, 2005Ratiopharm GmbhMethod for the production of statins
WO2005063728A2Dec 23, 2004Jul 14, 2005Teva Pharmaceutical Industries Ltd.Process for preparation of statins with high syn to anti ratio
WO2006067456A2Dec 22, 2005Jun 29, 2006Astrazeneca Uk LimitedProcess for preparing rosuvastatin
WO2006089401A1Feb 21, 2006Aug 31, 2006Apotex Pharmachem Inc.An improved process for the preparation of atorvastatin and intermediates
WO2007007119A1Jul 3, 2006Jan 18, 2007Astrazeneca Uk LimitedProcesses for the manufacture of rosuvastatin and intermediates
Non-Patent Citations
Reference
1Anne et al. "Enantioselective synthesss of key A-ring precursors of 1alpha, 25-dihydroxyvitamin D3 and analogues" Synlett 9:1435-1437 (1999).
2Anne et al. "Enantioselective synthesss of key A-ring precursors of 1α, 25-dihydroxyvitamin D3 and analogues" Synlett 9:1435-1437 (1999).
3Beletskaya et al., "The heck reaction as a sharpening stone of palladium catalysis," Chem. Rev., 2000 100(8);3009-3066.
4Bhaskar Reddy et al. "Enantioselective synthesis of beta-hydroxy delta-lactones: a new approach to the synthetic congeners of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors" J. Org. Chem. 56(20):5752-5754 (1991).
5Bhaskar Reddy et al. "Enantioselective synthesis of β-hydroxy δ-lactones: a new approach to the synthetic congeners of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors" J. Org. Chem. 56(20):5752-5754 (1991).
6Blandin et al. "One-pot and sequential asymmetric hydrogenation of beta,delta-diketoesters into functionalized 1,3-diols: From anti- to syn-stereoselectivity" European Journal of Organic Chemistry 12:3421-3427 (1999).
7Blandin et al. "One-pot and sequential asymmetric hydrogenation of β,δ-diketoesters into functionalized 1,3-diols: From anti- to syn-stereoselectivity" European Journal of Organic Chemistry 12:3421-3427 (1999).
8BouzBouz et al. "Regioselective Cross-Metathesis Reaction Induced by Steric Hindrance" Organic Letters 6(20):3465-3467 (2004).
9Bovy et al. "Synthesis of Heterocyclic beta-Amino Acids. A convenient preparation of beta-Amino-5-pyrimidinepropanoic acid and derivatives" Tetrahedron Letters 34(50):8015-8018 (1993).
10Bovy et al. "Synthesis of Heterocyclic β-Amino Acids. A convenient preparation of β-Amino-5-pyrimidinepropanoic acid and derivatives" Tetrahedron Letters 34(50):8015-8018 (1993).
11Breaux et al. "An Improved General Synthesis of 4-Aryl-5-Pyrimidinecarboxylates" J. Heterocyclic Chem. 18: 183 (1981).
12Casini et al. "Carbonic anhydrase inhibitors with strong topical antiglaucoma properties incorporating a 4-(2-amino-pyrimidin-4-yl-amino)-benzenesulfonamide scaffold" Journal of Enzyme Inhibition and Medicinal Chemistry 17(1):9-18 (2002).
13Castro et al. "A new synthesis of 3,5-dihydroxy-7-(1-pyrroly1)-6-heptenoic acids. A family of HMGCoA reductase inhibitors with antifungal activity" Tetrahedron Letters 43:1851-1854 (2002).
14De Luca et al. "Cellulose Beads: a New Versatile Solid Support for Microwave-Assisted Synthesis. Preparation of Pyrazole and Isoxazole Libraries" J. Comb. Chem. 5(4):465-471 (2003).
15Denmark et al. "The Chemistry of Trichlorosilyl Enolates. Aldol Addition Reactions of Methyl Ketones" J. Am. Chem. Soc. 122 (37):8837-8847 (2000).
16Dovlatyan et al. "Studies on functionally-substituted azines. 8. Synthesis and transformations of 1-arylsulfonylamido-4-methoxy-6-methylpyrimidines" Chemistry of Heterocyclic Compounds 36(11):1306-1313(2000).
17European Examination Report for European Application No. 05820940.4 dated Mar. 28, 2011.
18Evans et al. "Diastereoselective synthesis of protected syn 1,3-diols by base-catalyzed intramolecular conjugate addition of hemiacetal-derived alkoxide nucleophiles" J. Org. Chem. 58:2446-2453 (1993).
19Feuerstein et al. "A new efficient tetraphosphine/palladium catalyst for the Heck reaction of aryl halides with styrene or vinylether derivatives" Tetrahedron Letters 43:2191-2194 (2002).
20Grohe et al. "Synthese and Reaktionen von 2,4-Dichlorpyrimidin-5-carbon-saureestem" Liebigs Ann. Chem. 1025-1035 (1973).
21Gu et al. "Synthesis of ent-Haterumalide NA (ent-Oocydin A) Methyl Ester" Organic Letters 5(23):4385-4388 (2003).
22Hannah et al. "Structural studies on bioactive compounds. Part 29: palladium catalysed arylations and alkynylations of sterically hindered immunomodulatory 2-amino-5-halo-4,6-(disubstituted)pyrimidines" Bioorg Med Chem. 8(4):739-750 (2000).
23Hannah, D. R., et al.: "Structural Studies on Bioactive Compounds. Part 29: Palladium Catalysed Arylations and Alkynylations of Sterically Hindered Immunomodulatory 2-Amino-5-halo-4,6-(Disubstituted) pyrimidines", Bioorganic & Medicinal Chemistry, vol. 8(4), pp. 739-750, 2000.
24Hauser et al. "Synthesis of 5-phenyl-4,6-dimethyl-2-pyrimidol and derivatives from the cyclization of urea with 3-pheny1-2,4-pentanedione" Journal of Organic Chemistry 18(5): 588-593 (1953).
25Hauser, C. R., et al.: "Synthesis of 5-Phenyl-4,6-Pyrimidol and Derivatives from the Cyclization of Urea with 3-Phenyl-2,4-Pentanedione", Journal of Organic Chemistry, American Chemical Society, vol. 18, pp. 588-593, 1953.
26Hiyama et al. "Synthesis of Artificial HMG-CoA Reductase Inhibitors Based on the Olefination Strategy" Bull. Chem. Soc. Jpn. 68 (1):364-372 (1995).
27Kaneko et al. "Preparation of optically active 5,6-epoxyhexanoic acid esters as materials for physiologically active substances" Chemical Abstracts + Indexes, American Chemical Society, Columbus, US 118(11):832 (1993).
28Littke et al. "A Versatile Catalyst for Heck Reactions of Aryl Chlorides and Aryl Bromides under Mild Conditions" J. Am. Chem. Soc. 123(29):6989-7000 (2001).
29Littke et al. "Heck reactions in the presence of P(t-Bu) 3: Expanded scope and milder reaction conditions for the coupling of aryl chlorides" J. Org. Chem. 64:10-11 (1999).
30Ma et al. "Lanthanide triflate catalyzed Biginelli reaction. One pot synthesis of dihydropyrimidinones under solvent-free condition" J. Org. Chem. 65:3864-3868 (2000).
31Menges et al. "Oxidative Degradation of gamma-Butyrolactons into 1,3-Diols via a Criegee Rearrangement of Peroxosulfonates. An Enantioselective Synthesis of Compactin Lactone and its Diastereomer" Synlett 12:901-905 (1993).
32Menges et al. "Oxidative Degradation of γ-Butyrolactons into 1,3-Diols via a Criegee Rearrangement of Peroxosulfonates. An Enantioselective Synthesis of Compactin Lactone and its Diastereomer" Synlett 12:901-905 (1993).
33Miller et al. "Discovery of Aminopyridine-Based Inhibitors of Bacterial Enoyl-ACP Reductase (FabI)" J. Med. Chem. 45(15):3246-3256 (2002).
34Minami et al. "A Novel Enantioselective Synthesis of HMG Co-A Reductase Inhibitor NK-104 and a Related Compound" Tetrahedron letters 33(49):7525-7526 (1992).
35Minami et al. "Stereoselective Reduction of beta,delta-Diketo Esters Derived From Tartaric Acid. A Facile Route to Optically Active 6-oxo-3,5-syn-isopropylidenedioxyhexanoate, a Versatile Synthetic Intermediate of Artificial HMG Co-A Reductase Inhibitors" Tetrahedron Letters 34(3):513-516 (1993).
36Minami et al. "Stereoselective Reduction of β,δ-Diketo Esters Derived From Tartaric Acid. A Facile Route to Optically Active 6-oxo-3,5-syn-isopropylidenedioxyhexanoate, a Versatile Synthetic Intermediate of Artificial HMG Co-A Reductase Inhibitors" Tetrahedron Letters 34(3):513-516 (1993).
37Mohr et al. "Stereoselective synthesis of functionalized erythro/1,3-diols" Tetrahedron Letters 28(4):391-394 (1987).
38Moore et al. "Biosynthesis of the hypocholesterolemic agent mevinolin by Aspergillus terreus. Determination of the origin of carbon, hydrogen, and oxygen atoms by carbon-13 NMR and mass spectrometry" J. Am. Chem. Soc. 107(12): 3694-3701 (1985).
39Prasad et al. "A novel diastereroselective synthesis of lactone moiety of compactin" Tetrahedron Letters 25(23):2435-2438 (1984).
40Presentation given at the 20th International Congress of Heterocyclic Chemistry in Palermo, Aug. 1-5, 2005.
41Presentation given at the Gordon Conference on Heterocyclic Compounds, Salve Regina University, Newport, Rhode Island, Jul. 4-9, 2004.
42Sakaki et al. "Lipase-catalyzed asymmetric synthesis of 6-(3-chloro-2-hydroxypropyl)-1,3-dioxin-4-ones and their conversion to chiral 5,6-epoxyhexanoates" Tetrahedron: Asymmetry 2(5):343-346 (1991).
43Scialdone et al. "Building blocks for skipped polyols: syn-1,3-acetonides by chemoenzymatic synthesis from cycloheptatriene" Tetrahedron Letters 36(1):43-46 (1995).
44Shao et al. "Asymmetric hydrogenation of 3,5-Dioxoesters catalyzed by Ru-binap complex: A short step asymmetric synthesis of 6-substituted 5,6-dihydro-2-pyrones" Tetrahedron 49(10):1997-2010 (1993).
45Singer et al. "Catalytic, enantioselective dienolate additions to aldehydes: Preparation of optically-active acetoacetate aldol adducts" Journal of the American Chemical Society 117(49):12360-12361 (1995).
46Solladié et al. "Chrial Sulfoxides in Asymmetric Synthesis: Enantioselective Synthesis of the Lactonic Moiety of (+)-Compactin and (+)-Mevinolin. Application of a Compactin Analogue" J. Org. Chem. 60:7774-7777 (1995).
47Takahashi et al. "Synthesis of an artificial HMG-CoA reductase inhibitor NK-104 via a hydrosilylation-cross-coupling reaction" Bulletin of the Chemical Society of Japan 68(9):2649-2656 (1995).
48Vanden Eynde et al. "Microwave-mediated Regioselective Synthesis of. Novel Pyrimido[1,2-a]pyrimidines under Solvent-free Conditions" Tetrahedron 57(9):1785-1791 (2001).
49Virolleaud et al. "A straightforward synthesis of (E)-delta-alkenyl-beta,gamma-unsaturated delta-lactones by a tandem ring-closing/cross-coupling metathesis process" Tetrahedron Letters 44(44):8081-8084 (2003).
50Virolleaud et al. "A straightforward synthesis of (E)-δ-alkenyl-β,γ-unsaturated δ-lactones by a tandem ring-closing/cross-coupling metathesis process" Tetrahedron Letters 44(44):8081-8084 (2003).
51Watanabe et al. "Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonly Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors" Bioord. Med. Chem. 5(2):437-444 (1997).
52Watanabe, M., et al.: "Synthesis and Biological Activity of Methanesulfonamide Pyrimidine-And N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, A Novel Series of HMG-CoA Reductase Inhibitors", Bioorganic & Medicinal Chemistry, vol. 5(2), pp. 437-444, 1997.
53Wess et al. "Stereoselective Synthesis of HR 780 A New Highly Potent HMG-CoA Reductase Inhibitor", Tetrahedron Letters 31(18): 2545-2548 (1990).
54Zakrzewski et al. "Synthesis of syn- and anti-3,5-Dihydroxy-6-heptenoates from 2-Deoxy-d-ribose: Intermediates for Polyols Synthesis" Synlett 2:215-218 (2003).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US8614320Jun 14, 2012Dec 24, 2013Astrazeneca Uk LimitedPreparation of aminopyrimidine compounds
Classifications
U.S. Classification544/330, 544/331, 544/332
International ClassificationC07D239/36, C07D239/42
Cooperative ClassificationC07D239/36, C07D239/42
European ClassificationC07D239/36, C07D239/42
Legal Events
DateCodeEventDescription
Mar 2, 2011ASAssignment
Owner name: ASTRAZENECA UK LIMITED, UNITED KINGDOM
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUTTERS, MICHAEL;LENGER, STEVEN ROBERT;MURRAY, PAUL MICHAEL;AND OTHERS;REEL/FRAME:025890/0992
Effective date: 20070502
Mar 25, 2015FPAYFee payment
Year of fee payment: 4